Abstract: Provided is a cosmetic composition including ceramides and a sphingolipid. A composition including two or more different ceramides and a sphingolipid, according to an embodiment, has the activity of increasing a ceramide content in the skin, increasing the expression level of aquaporin 3, increasing the expression level of fillaggrin, increasing the expression level of loricrin, increasing the expression level of involucrin, and increasing the skin thickness, and thus can be effectively used for improving skin conditions.

Abstract: A vehicle-to-everything (V2X) communication-based electronic toll collection system (ETCS) according to an embodiment of the present invention includes at least one roadside unit (RSU), a token issuer checking a de-identified token of a vehicle by communicating with an on-board unit (OBU) of the vehicle via the at least one roadside unit, and a clearing house communicating with the token issuer and charging a toll to a driver/owner of the vehicle. The token issuer generates toll information of the vehicle based on the de-identified token of the vehicle and location information of the at least one roadside unit involved in checking the de-identified token.

Abstract: Proposed is a precursor composition for forming a metal film including a zirconium compound represented by any one of Chemical Formulas 1 to 3 and a hafnium compound represented by any one of Chemical Formulas 4 to 6.

Abstract: Provided a liquid crystal composition including ceramide, a method of preparing the same, and a cosmetic composition including the same. According to a liquid crystal composition including various types of ceramide of an aspect and a method of preparing the same, the liquid crystal composition not only has high liquid crystal stability that liquid crystal is maintained even after 4 weeks at a high temperature, but also activities of increasing an amount of ceramide, increasing an expression level of aquaporin 3, increasing an amount of filaggrin, increasing an expression level of hyaluronic acid, increasing an expression level of loricrin, increasing an expression level of involucrin, and increasing a thickness of the skin, resulting in effects usefully available for amelioration of the skin conditions.

Abstract: The present disclosure provides a platform system for transmitting a video in real time with ultra-low latency, the platform system including: a caster unit (100) configured to encode and transmits a video signal provided from one or a plurality of video sources (110) through a network communication network; a platform server (200) configured to provide the video signal transmitted from the caster unit in a streaming manner; and a user terminal (300) configured to be provided with the video signal from the platform server in a streaming manner. The platform system and method for transmitting a video in real time with ultra-low latency according to the present disclosure has the advantage that it is possible to provide an ultra-low latency service anytime anywhere as long as the internet is connected by enabling real-time transmission of an end-to-end video signal.

Abstract: The present disclosure provides an apparatus and method for encoding a video with ultra-low latency, the apparatus including: one or a plurality of video sources configured to provide a video signal; an encoder configured to encode the video signal provided through the video source and provided for each of the video sources; and a caster configured to transmit video data encoded by the encoder to the outside through a network communication network. Accordingly, the present disclosure can transmit a video with ultra-low latency, so a video service is possible in real time anytime anywhere as long as the internet is connected, whereby there is the advantage that the present disclosure can be applied to various fields of 4th industry such as autonomous driving, unmanned drone operation, driving of unmanned heavy equipment, robot control, a remote medical service, VR/AR, an intelligent CCTV, a smart city?factory, provision of traffic information, etc.

Abstract: A composite pad and a battery cell assembly and a battery module including the composite pad are disclosed. In some implementations, the battery cell assembly comprises a plurality of battery cells arranged in a direction, and one or more pads, each pad disposed between two adjacent battery cells of the plurality of battery cells, at least one of the one or more pads including a pad body with elasticity, and a heat generating part coupled to the pad body and connected to an edge of the at least one of the one or more pads and configured to generate heat upon application of electric power to the heat generating part.

Abstract: A display device includes a substrate including an active area having pixels and a non-active area including a pad region. A pad electrode is disposed in the pad region and includes a first pad electrode and a second pad electrode disposed on the first pad electrode. A first insulating pattern is interposed between the first and second pad electrodes. In a plan view, the first insulating pattern is positioned inside the first pad electrode, and a portion of the second pad electrode overlapping the first insulating pattern protrudes further from the substrate in a thickness direction than a portion of the second pad electrode not overlapping the first insulating pattern. The second pad electrode directly contacts a portion of the upper surface of the first pad electrode. In a plan view, an area of the second pad electrode is greater than an area of the first pad electrode.

Abstract: Provided are a method of preparing an antibody with a regulated, sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content, a method of preparing a high-quality population of antibodies by regulating the sugar content of the antibody to a desired content, and a population of antibodies prepared by the method. Further, provided is a method of regulating the antibody sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content. Furthermore, provided is a medium composition, for regulating the antibody sugar chain content, the medium composition including glycerol as an additive for regulating the antibody sugar chain content.

Abstract: The present invention relates to a vector comprising a polynucleotide encoding a modified glutamine synthetase (GS), and a method for preparing a target protein employing the same. More particulary, the present invention relates to a modified GS having an increased sensitivity to a glutamine synthetase (GS) inhibitor, a polynucleotide encoding the modified GS, a vector comprising the polynucleotide, a transformat comprising the vector, and a method for preparing a target protein using the transformat.

Abstract: Provided are a method of preparing an antibody with a regulated, sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content, a method of preparing a high-quality population of antibodies by regulating the sugar content of the antibody to a desired content, and a population of antibodies prepared by the method. Further, provided is a method of regulating the antibody sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content. Furthermore, provided is a medium composition, for regulating the antibody sugar chain content, the medium composition including glycerol as an additive for regulating the antibody sugar chain content.

Abstract: The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (DLL4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and Notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.

Abstract: The present invention relates to a vector comprising a polynucleotide encoding a modified glutamine synthetase (GS), and a method for preparing a target protein employing the same. More particularly, the present invention relates to a modified GS having an increased sensitivity to a glutamine synthetase (GS) inhibitor, a polynucleotide encoding the modified GS, a vector comprising the polynucleotide, a transformant comprising the vector, and a method for preparing a target protein using the transformant.

Abstract: The present invention relates to a method for separating and preparing a TNFR-Fc fusion protein using hydrophobic interaction chromatography (HIC). More particularly, the present invention relates to a method for separating and preparing a highly pure active protein from clipped proteins due to displacement effect by adjusting the conductivity of a protein sample using a high concentration of salt solution and by adjusting a loading amount thereof, and a TNFR-Fc fusion protein prepared by the method.

Abstract: The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (DLL4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and Notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.

Abstract: The present invention relates to a vector comprising a polynucleotide encoding a modified glutamine synthetase (GS), and a method for preparing a target protein employing the same. More particularly, the present invention relates to a modified GS having an increased sensitivity to a glutamine synthetase (GS) inhibitor, a polynucleotide encoding the modified GS, a vector comprising the polynucleotide, a transformant comprising the vector, and a method for preparing a target protein using the transformant.

Abstract: The present invention relates to a method for separating and preparing a TNFR-Fc fusion protein using hydrophobic interaction chromatography (HIC). More particularly, the present invention relates to a method for separating and preparing a highly pure active protein from clipped proteins due to displacement effect by adjusting the conductivity of a protein sample using a high concentration of salt solution and by adjusting a loading amount thereof, and a TNFR-Fc fusion protein prepared by the method.